Regulated Industries Making Irreversible AI Bets | Ep. 1
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Regulated Industries Making Irreversible AI Bets | Ep. 1
-
ナレーター：
-
著者：
(00:01:12) Haleon's $5B Microsoft Commitment
(00:02:15) Government AI Gatekeeping Hardens
(00:03:18) Claude Sonnet 5 Mid-Tier Agentic Push
(00:03:48) California Statewide Claude Deal
(00:04:24) Engram's $98M Memory Layer Bet
(00:04:56) Key Signals to Watch
Regulated industries are locking in major AI commitments before the governance frameworks around them are fully formed — and today's episode maps exactly where those bets are being placed and what's still missing.
The FDA is replacing its static device-approval model with a lifecycle framework built around Predetermined Change Control Plans, letting medical AI algorithms evolve continuously without fresh submissions. The architecture is ambitious. The enforcement path when an algorithm quietly drifts in a clinical setting is still murky.
Haleon — maker of Sensodyne and Advil — just signed a five-year, multi-billion-dollar Microsoft deal deploying Copilot agents and Azure infrastructure across 25,000 employees. The story isn't the size; it's the single-vendor lock-in logic spreading across pharma and healthcare, and the unresolved liability question when Copilot agents start generating product claims.
Government gatekeeping of frontier models is hardening into a pattern without statutory footing. GPT-5.6 shipped to roughly 20 authorized organizations under national security review. Anthropic's Fable 5 export restrictions were lifted, while Mythos 5 stays restricted. Labs are complying with government pulls on model access that have no clear legal framework — a real planning risk for any developer building on these platforms.
Also covered: Claude Sonnet 5 hits 63.2% on agentic coding benchmarks at introductory pricing that narrows the mid-tier-to-premium gap faster than expected. California makes Claude the first AI tool available statewide. And Engram emerges from stealth with $98M from General Catalyst, Kleiner Perkins, and Sequoia to build an enterprise memory layer — with internal benchmarks only so far.
Two signals to watch: the FDA's first enforcement action under its drift-detection framework, and whether government model-gatekeeping criteria ever get formalized.
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません